Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Motor hyperactivity, inattention
3. Stimulants in autism
4. MPH in children with PDD and hyperactivity
5. Test-dose phase
6. Crossover phase
7. Crossover phase - other ABC subscale
8. Categorical response (1)
9. Categorical response (2)
10. MPH summary
11. Treating hyperactivity: other medications
12. Atomoxetine in higher functioning PDD
13. Atomoxetine in PDD with ADHD symptoms
14. Interfering repetitive behavior
15. Serotonin reuptake inhibitors (SRIs)
16. SRIs in autism
17. Citalopram in PDDs
18. Irritability (aggression, self-injury, severe tantrums)
19. Typical antipsychotics
20. Atypical antipsychotics
21. Clozapine
22. Risperidone in children with autism
23. Acute Risperidone trial
24. Acute Risperidone trial results (1)
25. Acute Risperidone trial results (2)
26. Baseline and endpoint ABC scores by group
27. Risperidone parent management training trial (1)
28. Risperidone parent management training trial (2)
29. Olanzapine vs. Haloperidol
30. Olanzapine-double blind, placebo controlled study
31. Quetiapine
32. Ziprasidone (1)
33. Ziprasidone (2)
34. Aripiprazole in Asperger's and PDD NOS (1)
35. Aripiprazole in Asperger's and PDD NOS (2)
36. Aripiprazole in autism - flexible dose study
37. Aripiprazole in autism - fixed dose study
38. Impaired social relatedness
39. Medications for social impairment in autism
40. D-Cycloserine in children with autism
41. Future directions
42. Christian Sarkine Autism Treatment Center

Topics Covered

• Identification of target symptoms
• Pharmacotherapy of motor hyperactivity and inattention
• Pharmacotherapy of Interfering repetitive behavior
• Pharmacotherapy of Irritability (aggression, self-injury, severe tantrums)
• Pharmacotherapy of impaired social relatedness
• Future directions for research

Links

Series:

• Autism and Autism Spectrum Disorders

Categories:

• Clinical Practice
• Neuroscience
• Pharmaceutical Sciences

Therapeutic Areas:

• Neurology

Talk Citation

Publication History

• Published on July 27, 2011

Financial Disclosures

• Prof. Christopher J. McDougle has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.